Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Validation of a Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma: a Multicenter Cohort Study

NCT06656039 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06656039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06656039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Validation of a Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma: a Multicenter Cohort Study
Lead sponsor
RenJi Hospital
Phase
Observational
Overall status
Completed
Start date
January 1, 2024
Completion date
October 10, 2024
Enrollment
1,200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma, clear cell